Canaccord Genuity Maintains Buy on Fractyl Health, Lowers Price Target to $39
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
Canaccord Genuity analyst Whitney Ijem maintains Fractyl Health (NASDAQ:GUTS) with a Buy and lowers the price target from $96 to $39.
Canaccord Genuity analyst Whitney Ijem maintains Fractyl Health (NASDAQ:GUTS) with a Buy and lowers the price target from $96 to $39.